Treatment Outcomes for Patients with CLL and SLL Treated with First Line Ibrutinib Versus Chemoimmunotherapy
More research is presented again, proving that targeted therapies, in this case, ibrutinib, are significantly superior to chemoimmunotherapy (CIT) in front-line therapy for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL / SLL).